Texas Permanent School Fund Corp lifted its stake in Artivion, Inc. (NYSE:AORT – Free Report) by 14.5% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 39,063 shares of the company’s stock after purchasing an additional 4,934 shares during the quarter. Texas Permanent School Fund Corp owned about 0.09% of Artivion worth $1,002,000 as of its most recent SEC filing.
Other institutional investors also recently bought and sold shares of the company. GAMMA Investing LLC increased its stake in Artivion by 38.6% during the 1st quarter. GAMMA Investing LLC now owns 1,814 shares of the company’s stock valued at $38,000 after purchasing an additional 505 shares in the last quarter. Louisiana State Employees Retirement System grew its holdings in shares of Artivion by 3.1% during the second quarter. Louisiana State Employees Retirement System now owns 19,900 shares of the company’s stock valued at $510,000 after buying an additional 600 shares during the last quarter. nVerses Capital LLC acquired a new position in shares of Artivion in the 2nd quarter valued at $28,000. Price T Rowe Associates Inc. MD raised its stake in Artivion by 5.1% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 33,690 shares of the company’s stock worth $713,000 after acquiring an additional 1,634 shares during the last quarter. Finally, Bank of New York Mellon Corp lifted its position in Artivion by 0.7% during the 2nd quarter. Bank of New York Mellon Corp now owns 301,992 shares of the company’s stock worth $7,746,000 after acquiring an additional 2,018 shares during the period. 86.37% of the stock is currently owned by institutional investors and hedge funds.
Artivion Stock Up 0.3 %
Shares of AORT opened at $25.21 on Friday. The company has a market capitalization of $1.05 billion, a price-to-earnings ratio of -105.04 and a beta of 1.74. Artivion, Inc. has a 52 week low of $12.16 and a 52 week high of $29.24. The stock’s 50-day moving average price is $26.03 and its 200-day moving average price is $23.64. The company has a quick ratio of 4.04, a current ratio of 5.63 and a debt-to-equity ratio of 1.07.
Wall Street Analysts Forecast Growth
A number of research analysts have recently weighed in on AORT shares. Needham & Company LLC reissued a “buy” rating and issued a $30.00 price objective on shares of Artivion in a report on Friday, August 9th. Lake Street Capital increased their price target on shares of Artivion from $28.00 to $30.00 and gave the stock a “buy” rating in a report on Tuesday, July 2nd. Stifel Nicolaus lifted their price objective on shares of Artivion from $28.00 to $30.00 and gave the company a “buy” rating in a research note on Friday, September 13th. Finally, Oppenheimer increased their price objective on shares of Artivion from $25.00 to $30.00 and gave the stock an “outperform” rating in a research note on Friday, August 9th.
Read Our Latest Stock Analysis on AORT
Insider Buying and Selling
In other Artivion news, Director Anthony B. Semedo sold 9,709 shares of Artivion stock in a transaction on Tuesday, August 13th. The shares were sold at an average price of $24.99, for a total value of $242,627.91. Following the completion of the transaction, the director now owns 34,159 shares of the company’s stock, valued at $853,633.41. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In other news, SVP Jean F. Holloway sold 3,167 shares of the company’s stock in a transaction that occurred on Monday, August 26th. The stock was sold at an average price of $26.55, for a total transaction of $84,083.85. Following the completion of the transaction, the senior vice president now directly owns 161,932 shares of the company’s stock, valued at approximately $4,299,294.60. The sale was disclosed in a filing with the SEC, which is available at this link. Also, Director Anthony B. Semedo sold 9,709 shares of the stock in a transaction that occurred on Tuesday, August 13th. The shares were sold at an average price of $24.99, for a total value of $242,627.91. Following the transaction, the director now owns 34,159 shares in the company, valued at approximately $853,633.41. The disclosure for this sale can be found here. Over the last three months, insiders have sold 24,679 shares of company stock valued at $626,518. Corporate insiders own 8.10% of the company’s stock.
Artivion Profile
Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.
Read More
- Five stocks we like better than Artivion
- High Flyers: 3 Natural Gas Stocks for March 2022
- Analysts Predict 85% Upside for Wave Life Sciences After Rate Cut
- About the Markup Calculator
- FedEx Stock Dips: Another Reason to Fear Recession Is Near
- What is a buyback in stocks? A comprehensive guide for investors
- The Half-Penny Revolution: Will SEC’s Reform Benefit Investors?
Want to see what other hedge funds are holding AORT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Artivion, Inc. (NYSE:AORT – Free Report).
Receive News & Ratings for Artivion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Artivion and related companies with MarketBeat.com's FREE daily email newsletter.